Chemotherapy and the Immune System PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Chemotherapy and the Immune System PDF full book. Access full book title Chemotherapy and the Immune System by L. H. Chappell. Download full books in PDF and EPUB format.
Author: L. H. Chappell
Publisher: Cambridge University Press
ISBN: 9780521448352
Category : Medical
Languages : en
Pages : 116
Get Book Here
Book Description
This specially commissioned text covers a range of topics relating to chemotherapy and the immune system.
Author: L. H. Chappell
Publisher: Cambridge University Press
ISBN: 9780521448352
Category : Medical
Languages : en
Pages : 116
Get Book Here
Book Description
This specially commissioned text covers a range of topics relating to chemotherapy and the immune system.
Author: Enrico Mihich
Publisher: Elsevier
ISBN: 1483259005
Category : Health & Fitness
Languages : en
Pages : 415
Get Book Here
Book Description
Immunity, Cancer, and Chemotherapy focuses on the interference of drugs on antibody response and transplantation immunity. The selection first offers information on the effects of immunosuppressive drugs on cellular changes after antigenic stimulation and specialized cell function in the lymphoid and reticuloendothelial cell series. Topics include effects of immunosuppressive drugs on the sensitization process; cellular changes in lymphoid tissue following sensitization; and demonstration of differences in antigen handling among cells of the reticuloendothelial system. The text also takes a look at allogeneic inhibition and its possible relation to cell-bound immunity in vitro and the effects of immunosuppressive drugs at various stages of differentiation of immunologically competent cells. The publication examines a study of antibody-containing cells in the course of immunization and cellular differentiation during immune responses studied with electron microscope and radioautography. The text also elaborates on ambiguity in the translation of genetic code into proteins, induced by aminoglycoside antibiotics and immunosuppressive agents and cellular kinetics of immune response. The selection is a dependable source of information for readers interested in effects of drugs on antibody response and transplantation immunity.
Author: Gerhard Pulverer
Publisher:
ISBN:
Category : Anti-infective agents
Languages : en
Pages : 264
Get Book Here
Book Description
Author: Robert Gorter, M.D., Ph.D.
Publisher: North Atlantic Books
ISBN: 1583942831
Category : Health & Fitness
Languages : en
Pages : 385
Get Book Here
Book Description
Fighting Cancer describes the Gorter Model, an integrative, nontoxic approach to cancer treatment that mobilizes the immune system. It was developed by Robert Gorter, MD, PhD, who in 1976 recovered from Stage IV testicular cancer by using nontoxic treatment and no chemotherapy or radiation. Based on self-experience, extensive research, and decades of clinical practice, the treatment consists of supporting the immune system using fever therapy (hyperthermia), inoculation with immune cells, the use of the botanical mistletoe (Viscum album)—the single most commonly prescribed anti-cancer medication in much of Europe—supportive nutrients, and diet and lifestyle changes. Organized into three parts, Fighting Cancer presents a clear overview of the model, the research behind it, and strategies for strengthening natural immunity. Emphasizing stress reduction and minimizing toxic exposure, the authors provide practical guidance for patients: questions to ask doctors after diagnosis and advice for evaluating options, gathering information, and getting second opinions. Included are powerful testimonials from patients—most of whom have outlived their prognosis and, in some cases, achieved complete and sustained remission.
Author: Gabriele Multhoff
Publisher: Frontiers E-books
ISBN: 2889191397
Category :
Languages : en
Pages : 131
Get Book Here
Book Description
Numerous developments in molecular biology have led to an explosive growth in the knowledge underlying mechanisms of carcinogenesis, cell signalling, tumor progression and development of metastasis. However, cure of cancer is still hampered by the inherited capacity of tumors to become resistant to standard therapies, to metastasize from their initial location and to proliferate in other tissue compartments. Radiotherapy is one of the main treatment modalities to achieve locoregional tumor control. However, the treatment of distant metastases further remains to be a challenge. In this special topic we are interested to elucidate immunological aspects which are initiated and affected by radiotherapy. We also aim to describe the development of innovative immunological strategies from a preclinical stage to clinical application which could be combined with standard radiotherapeutic approaches. A special interest will also deal with the effects of radiotherapy on tumor initiating cells as well as on the tumor microenvironment. Last but not least the effects of different irradiation sources and qualities such as photones, protones and heavy ions will be analyzed with respect to immunological outcome.
Author: Haidong Dong
Publisher: Springer Nature
ISBN: 3031594754
Category :
Languages : en
Pages : 228
Get Book Here
Book Description
Author: Paul D. Rennert
Publisher: Springer
ISBN: 3319298275
Category : Medical
Languages : en
Pages : 285
Get Book Here
Book Description
Cancer care is undergoing a radical transformation as novel technologies are directed toward new treatments and personalized medicine. The most dramatic advances in the treatment of cancer have come from therapeutics that augment the immune response to tumors. The immune checkpoint inhibitors are the best-known and most highly advanced examples of Immune Therapeutics targeting tumor cells and include approved antibody drugs directed at the cell surface proteins CTLA4 and PD-1. These are now considered foundational treatments for several solid tumor indications, and that list of indications is growing quickly. More broadly, antibodies have become workhorse molecules across the entire immunotherapy landscape. Antibodies to novel targets modulate the activity of diverse immune cell regulatory proteins. Engineered antibodies can induce tumor cell death or expose tumor cells to poisonous toxins (ADCC and ADC, respectively). Bi-specific antibodies can engage multiple tumor targets simultaneously, or can redirect lymphocytes to attack tumor cells. The antigen-binding domains within antibodies can be spliced onto cell stimulatory domains and transduced into T cells or NK cells, creating remarkable tumor-specific cellular therapeutics (CAR-T, CAR-NK). Beyond antibody-based therapies there are highly diverse and differentiated technology tool kits being applied to immunotherapy. Small molecule drugs are being developed to attack the tumor microenvironment, novel tumor vaccine approaches are showing great promise, patient lymphocytes are being isolated, expanded and reintroduced to patients, gene-editing techniques are becoming widely deployed, and a vast number of new tumor targets, and mutated tumor proteins (neoantigens), are being discovered. The past decade has seen unprecedented success in the treatment of diverse cancers. The authors of this volume have been asked to not only review progress to date, but importantly, to look ahead, and anticipate the evolution of cancer treatment across diverse Immune Therapeutic approaches. Our hypothesis is that the advances we are seeing across the immunotherapy landscape will further evolve and synergize, leading us finally to outright cures for many cancers.
Author: Haidong Dong
Publisher: Springer
ISBN: 3319706225
Category : Medical
Languages : en
Pages : 164
Get Book Here
Book Description
This book provides patients and their physicians (especially “non-oncologist” health care providers) with a clear and concise introduction to cancer immunotherapy, which, unlike traditional forms of cancer therapy, acts by boosting the patient’s own immune system to fight cancer. The unique features of cancer immunotherapy make its management, monitoring and side-effects different from those of traditional cancer therapy. Especially novel are the side effects of cancer immunotherapy, necessitating greater awareness for both patients and physicians in order to minimize complications of therapy. The patient-friendly, concise, easy-to-understand, and up-to-date knowledge presented in this book will inform patients about the benefits and risks of cancer immunotherapy, and help them and their care providers to understand how immunotherapy would control their unique disease. Researchers and academic professionals in the field of cancer immunotherapy will also find clear and useful information to help them communicate with patients or address unresolved problems. Some key features of the book are: Expertise. All editors and authors are scientists and oncologists specializing in cancer immunotherapy, and are involved in scientific discovery from the early stage of immune-checkpoint inhibitors to today’s daily patient care. Their insights, expertise and experience guarantee the high quality and authority in the science, medicine and practice of cancer immunotherapy. Patient-friendly. This book is written for cancer patients in order to meet their needs when considering immunotherapy. As an educational tool, this book will help the reader balance the risks and benefits based on both science and clinical facts, and therefore to make the best choice in receiving or withdrawing from immunotherapy. Disease Specificity. Cancer is a complicated disease involving multiple stages and pathology. Its response to immunotherapy is individualized and varies depending on cancer types. The authors’ expertise in treating different types of cancers, including melanoma, lung, kidney, bladder, and lymphoma, provides disease-specific insights in applying immunotherapy to each disease.
Author: Abhishek D Garg
Publisher: Frontiers Media SA
ISBN: 2889198383
Category : Immunologic diseases. Allergy
Languages : en
Pages : 147
Get Book Here
Book Description
Classically, anti-cancer therapies have always been applied with the primary aim of tumor debulking achieved through widespread induction of cancer cell death. While the role of host immune system is frequently considered as host protective in various (antigen-bearing) pathologies or infections yet in case of cancer overtime it was proposed that the host immune system either plays no role in therapeutic efficacy or plays a limited role that is therapeutically unemployable. The concept that the immune system is dispensable for the efficacy of anticancer therapies lingered on for a substantial amount of time; not only because evidence supporting the claim that anti-cancer immunity played a role were mainly contradictory, but also largely because it was considered acceptable (and sometimes still is) to test anticancer therapies in immunodeficient mice (i.e. SCID/athymic mice lacking adaptive immune system). This latter practice played a detrimental role in appreciating the role of anticancer immunity in cancer therapy. This scenario is epitomized by the fact that for a long time the very existence of cancer-associated antigens or cancer-associated ‘danger signaling’ remained controversial. However, over last several years this dogmatic view has been considerably modified. The existence of cancer-associated antigens and ‘danger signaling’ has been proven to be incontrovertible. These developments have together paved way for the establishment of the attractive concept of “immunogenic cell death” (ICD). It has been established that a restricted class of chemotherapeutics/targeted therapeutics, radiotherapy, photodynamic therapy and certain oncolytic viruses can induce a form of cancer cell death called ICD which is accompanied by spatiotemporally defined emission of danger signals. These danger signals along with other factors help cancer cells undergoing ICD to activate host innate immune cells, which in turn activate T cell-based immunity that helps eradicate live (or residual) surviving cancer cells. The emergence of ICD has been marred by some controversy. ICD has been criticized to be either experimental model or setting-specific or mostly a concept based on rodent studies that may have very limited implications for clinical application. However, in recent times it has emerged (through mainly retrospective or prognostic studies) that ICD can work in various human clinical settings hinting towards clinical applicability of ICD. However a widespread consensus on this issue is still transitional. In the current Research Topic we aimed to organize and intensify a discussion that strives to bring together the academic and clinical research community in order to provide a background to the current state-of-the-art in ICD associated bench-side research and to initiate fruitful discussions on present and future prospects of ICD translating towards the clinical, bedside reality.
Author: Laurence Zitvogel
Publisher: Springer
ISBN: 3319624318
Category : Medical
Languages : en
Pages : 700
Get Book Here
Book Description
In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field.
